Refine
Is part of the Bibliography
- yes (137)
Year of publication
Document Type
- Journal article (126)
- Doctoral Thesis (10)
- Report (1)
Language
- English (137) (remove)
Keywords
- melanoma (18)
- Merkel cell carcinoma (14)
- therapy (6)
- psoriasis (5)
- PD-1 (4)
- dermatology (4)
- polyomavirus (4)
- uveal melanoma (4)
- Anaphylaxis (3)
- Apoptosis (3)
- BRAF (3)
- Medizin (3)
- T cells (3)
- apoptosis (3)
- cell staining (3)
- children (3)
- drug adverse reaction (3)
- drug allergy (3)
- drug hypersensitivity (3)
- immune checkpoint blockade (3)
- immunohistochemistry (3)
- Allergy (2)
- B-cell lymphoma (2)
- COVID-19 (2)
- CTLA-4 (2)
- Germany (2)
- Human papillomavirus (2)
- Immunotherapy (2)
- Invasion (2)
- MAP-Kinase (2)
- Melanom (2)
- Merkel cell polyomavirus (2)
- Merkel-Zellkarzinom (2)
- PD-L1 (2)
- TRRAP (2)
- Th17 (2)
- Tumorzelle (2)
- Zellmigration (2)
- allergy (2)
- anaphylaxis (2)
- angiogenesis (2)
- autoantibodies (2)
- biologics (2)
- bullous pemphigoid (2)
- diagnosis (2)
- immunology (2)
- immunotherapy (2)
- inflammation (2)
- large T antigen (2)
- machine learning (2)
- mastocytosis (2)
- melanomas (2)
- miRNA (2)
- multiple sclerosis (2)
- pemphigus (2)
- pemphigus foliaceus (2)
- pemphigus vulgaris (2)
- penicillin allergy (2)
- penicillin hypersensitivity (2)
- peptide vaccination (2)
- polymavirus (2)
- treatment resistance (2)
- tumor (2)
- urticaria (2)
- A375 (1)
- ACE inhibitor (1)
- ARCI (1)
- ARCI EM type III (1)
- Allergie (1)
- Autoantikörper (1)
- Autoimmunity (1)
- Autoimmunität (1)
- B cells (1)
- B-cells (1)
- B7-H1 Antigen (1)
- BARF-mutated melanoma (1)
- BP180 (1)
- BRAF inhibition (1)
- BRAF mutation (1)
- BRAF mutations (1)
- BRN-3A (1)
- Background Epithelioid haemangioma (1)
- Basophil activation test (1)
- Becker naevus (1)
- Becker naevus syndrome (1)
- Beta-blocker (1)
- Biomarker (1)
- Blasen bildende Autoimmundermatosen (1)
- Bowen’s disease, periungual (1)
- Bronchialasthma (1)
- Bullous pemphigoid (1)
- CD10 (1)
- CD105 antigen (1)
- CD274 (1)
- CD30 (1)
- CD34 antigen (1)
- CD8(+) (1)
- COX2 expression (1)
- CRISPR (1)
- CTLA-4 Antigen (1)
- Ca\(^{2+}\) signalling (1)
- Cancer Cell (1)
- Clinical trials (1)
- Covid-19 (1)
- Crohn disease (1)
- Crosstalk (1)
- Cutaneous lymphoma (1)
- Cutaneous metastatic Crohn’s disease (1)
- Cx43 (1)
- DNA (1)
- DNA damage (1)
- DNA repair (1)
- Dendritische Zelle (1)
- Desmoplakin (1)
- Diagnose (1)
- Double sensitization (1)
- Drug Therapy, Combination (1)
- Drug allergy (1)
- Drug reaction (1)
- EBER in situ hybridization (1)
- EGR1 (1)
- ERBB receptors (1)
- EVER1 (1)
- EVER2 (1)
- Endothel (1)
- Endothelium (1)
- Enoxaparin (1)
- Epigenetic regulation (1)
- Epigenetics (1)
- Field sting (1)
- Flt3L (1)
- Forkhead Transcription Factors (1)
- Forkhead-Box-Proteine (1)
- FoxO transcription factors (1)
- FoxO3 (1)
- G Protein (1)
- GNA11 (1)
- GNAQ (1)
- GSK3 (1)
- Granulozyten (1)
- Grundsubstanz (1)
- HDAC (1)
- HT29 cells (1)
- Hair follicle (1)
- Hautkrebs (1)
- Heparin (1)
- Hippo signaling (1)
- Histogenese (1)
- Histogenesis (1)
- Histone deacetylase (1)
- Honey bee (1)
- Hymenoptera venom (1)
- Hypersensitivity (1)
- IFN (1)
- IL-4/IL-13 inhibitor (1)
- IL‐10 (1)
- Immediate-type (1)
- Immune Escape (1)
- Immune-related adverse event (1)
- Immunoadsorption (1)
- Immunoapheresis (1)
- Immunoglobulin E (1)
- Immunologische Synapse (1)
- Immuntherapie (1)
- Integrine (1)
- Ipilimumab (1)
- JAK2 (1)
- Juvenile biventricular cardiomyopathy (1)
- Kaposi sarcoma (1)
- Karzinomzellen (1)
- Kerinokeratosis papulosa (1)
- Kollagen (1)
- Kollagenasen (1)
- Kollektive Invasion (1)
- Krebs <Medizin> (1)
- Krüppel-like factor (1)
- LIF (1)
- LRIG1 (1)
- LSD1 (1)
- Large T antigen (1)
- Leukozyt (1)
- Leukozyten (1)
- Lysine-specific methylase (1)
- MCC (1)
- MCPyV (1)
- MCV-negative (1)
- MEK5/ERK5 cascade (1)
- MHC class I chain-related protein (1)
- MICA (1)
- MICB (1)
- Malignant melanoma (1)
- Mastocytosis (1)
- Matrixproteasen (1)
- Maus (1)
- Melanoma (1)
- Minimal change disease (1)
- Molecular imaging (1)
- Mouse model of allergic airway inflammation (1)
- Multiphotonenmikroskopie (1)
- Mycobacterium marinum (1)
- Mycosis fungoides bullosa (1)
- NIPAL4 (1)
- NRF2 (1)
- Nail unit (1)
- Nekrose (1)
- Nfatc1 (1)
- Nivolumab (1)
- Non-steroidal anti-inflammatory drug (1)
- P53 (1)
- PD‐L1 (1)
- PEComa (1)
- PIK3CA mutations (1)
- PRAME (1)
- Palmoplantar keratoderma (1)
- Pathologic neovascularization (1)
- Pemphigoid gestationis (1)
- Peripheral eosinophils (1)
- Pityriasis lichenoides (1)
- Polyomavirus (1)
- Positron emission tomography (1)
- Programmed Cell Death 1 Receptor (1)
- Proteaseinhibitoren (1)
- Pseudo-allergy (1)
- RNA modification (1)
- RNA probe (1)
- Raman (1)
- Relapse (1)
- Risk factor (1)
- S2k guidelines (1)
- SARS-CoV-2 (1)
- SERS (1)
- STAT3 (1)
- Senescence (1)
- Skin (1)
- Skin Neoplasms (1)
- Somatostatin receptor expression (1)
- Stevens-Johnson syndrome (1)
- Sturge-Weber syndrom (1)
- Sunitinib (1)
- T antigen (1)
- T lymphocyte (1)
- T-Lymphozyt (1)
- T-Zellaktivierung (1)
- T-Zellhomöostase (1)
- T-antigen (1)
- T-antigens (1)
- T-cell reactivity (1)
- TNF alpha (1)
- TP53 (1)
- Targeted therapy (1)
- Therapie (1)
- Tr1 (1)
- Treatment failure (1)
- Tregs (1)
- Tubulin (1)
- Tumor Immunology (1)
- Tyrosine kinase inhibition (1)
- United States (1)
- V. saphena magna (1)
- Vespula (1)
- Waxy papulosis of childhood (1)
- XPA (1)
- Y-box binding protein 1 (1)
- YTHDF1 (1)
- acitretin (1)
- activation (1)
- adalimumab (1)
- adjuvant treatment (1)
- advanced cutaneous squamous cell carcinoma (1)
- adverse drug reaction (1)
- adverse event (1)
- age (1)
- agranulocytosis (1)
- akt (1)
- algorithm (1)
- allergies (1)
- allotype (1)
- aluminum granuloma (1)
- amoxicillin (1)
- ampicillin (1)
- anergy (1)
- angioedema (1)
- antagomiRs (1)
- antibiotic (1)
- antibody–drug conjugates (1)
- antitumor immunity (1)
- artesunate (1)
- aspirin‐exacerbated respiratory disease (1)
- asthma (1)
- at-home sampling (1)
- atherosclerosis (1)
- autoimmune blistering diseases (1)
- autoimmune disease (1)
- autoimmune diseases (1)
- autoimmune skin blistering disease (1)
- avelumab (1)
- bee (1)
- biomarker (1)
- biosimilar (1)
- bleomicina (1)
- bleomycin (1)
- blisters (1)
- blood (1)
- bone (1)
- breast cancer (1)
- brown band (1)
- buildup phase (1)
- bullae (1)
- c-flip (1)
- cDC2 subset (1)
- cancer (1)
- cancer microenvironment (1)
- cancer patients (1)
- cancer treatment (1)
- carcinoma cells (1)
- cartilage (1)
- case report (1)
- cell cycle (1)
- cell death (1)
- cell membranes (1)
- cell migration (1)
- cell rich blue nevus (1)
- cell viability testing (1)
- cell-death (1)
- cemiplimab (1)
- cesioflammea (1)
- checkpoint blocker (1)
- checkpoint inhibitor therapy (1)
- chemokine (1)
- chromatin regulator (1)
- cicatricial pemphigoid (1)
- classification (1)
- collagenases (1)
- collective invasion (1)
- collodion baby (1)
- combined targeted therapy (1)
- common blue nevus (1)
- comorbid diseases (1)
- comorbidity (1)
- congenital melanocytic nevi (1)
- conversion (1)
- copy number variations (1)
- coronavirus disease 2019 (1)
- cultured fibroplasts (1)
- cutaneous PEComa (1)
- cutaneous T-cell lymphoma and Merkel cell carcinoma (1)
- cutaneous T-cell-lymphoma (1)
- cutaneous adverse events (1)
- cutaneous angiosarcoma (1)
- cutaneous lupus erythematosus (1)
- cutaneous lymphomas (1)
- dabrafenib (1)
- dapsone (1)
- dendritic cell (1)
- dendritic cells (1)
- dermal melanocytosis (1)
- dermatite flagelada (1)
- differential gene expression (1)
- disease severity (1)
- domain (1)
- drug effectiveness (1)
- drug exanthema (1)
- drug monitoring (1)
- drug therapy (1)
- drug-induced liver injury (DILI) (1)
- eczematous dermatitis (1)
- efgartigimod (1)
- endemic pemphigus foliaceus (1)
- endothelium (1)
- environmental factors (1)
- eosinophils (1)
- epidermis (1)
- epigenetic reader (1)
- epigenetic silencing (1)
- epitranscriptome (1)
- exanthem (1)
- experience (1)
- expression (1)
- extracellular-regulated kinase 5 (1)
- family (1)
- fatty liver disease (1)
- ferroptosis (1)
- fixed drug eruption (1)
- flagellate dermatitis (1)
- flu-like symptoms (1)
- focal adhesion (1)
- fumaric acid esters (1)
- functional genetics (1)
- fungos shiitake (1)
- gene induction (1)
- genetic association (1)
- germline (1)
- glycogen synthase kinase 3 (1)
- gold nanoparticles (1)
- half-life (1)
- health economics (1)
- health insurance (1)
- health-care costs (1)
- heat shock response (1)
- hemangioma (1)
- hemorrhagic (1)
- henoch-schönlein purpura (1)
- hereditary alpha-tryptasemia (1)
- hidradenitis suppurativa (1)
- high-risk Prostate Cancer (1)
- histologic findings (1)
- histology (1)
- histone (1)
- histone methyltransferase PRDM8 (1)
- human (1)
- hydroxy-dabrafenib (1)
- hymenoptera (1)
- hypoplasia of fatty tissue (1)
- ichthyosis (1)
- immune cell infiltration (1)
- immune infiltration (1)
- immune suppression (1)
- immunohistochemistry techniques (1)
- immunological synapse (1)
- immunosuppression (1)
- immunotherapeutics (1)
- improvement (1)
- in vivo (1)
- in-vitro (1)
- in-vivo (1)
- indirect costs (1)
- inflammation-induced tissue demage (1)
- inflammatory disease (1)
- inguinal lymph node dissection (1)
- injection site reactions (1)
- inpatients (1)
- integrins (1)
- interferon (1)
- interferon beta (1)
- interferon-\(\beta\) (1)
- interleukins (1)
- interview (1)
- invasion (1)
- ipilimumab (1)
- keratinocytes (1)
- keratosis (1)
- kidney cancer (1)
- knockout (1)
- lactate dehydrogenase (1)
- laminin 332 (1)
- large cell transformation (1)
- leg cramps (1)
- lesions (1)
- leukozytes (1)
- lichen planus (1)
- life (1)
- liver metastasis (1)
- long-term outcome (1)
- lower body (1)
- lumps (1)
- lung cancer (1)
- lymphocytes (1)
- lymphoid hyperplasia (1)
- lymphoma (1)
- mRNA (1)
- mTOR (1)
- m\(^6\)A (1)
- macro-morphology (1)
- malignancy (1)
- malignant melanoma (1)
- management (1)
- matrix proteases (1)
- mechanotransduction (1)
- mediated apoptosis (1)
- medical students (1)
- melanin (1)
- melanocytes (1)
- melanocytic markers (1)
- melanoma cell (1)
- melanoma cells (1)
- melanoma malignancy (1)
- melanoma patients (1)
- membrane proteins (1)
- membrans proteins (1)
- mental health (1)
- mepacrine (1)
- metabolic disease (1)
- metastatic (1)
- methylation (1)
- miR-375 (1)
- micro-morphology (1)
- microRNA-221 (1)
- microvessel density (1)
- migraine (1)
- migration (1)
- migration and invasiveness (1)
- mitochondrial DNA (1)
- mitogen-activated protein kinase (1)
- moderate (1)
- mouse model (1)
- mtDNA (1)
- mucous membrane pemphigoid (1)
- multicenter (1)
- multiphoton microscopy (1)
- multiple myeloma (1)
- mycosis fungoides (1)
- necrotic cell death (1)
- neural crest factors (1)
- neurologic disease (1)
- nivolumab (1)
- nucleotide excision repair (1)
- oesophagogastroduodenoscopy (1)
- oncodermatology (1)
- oncogene-induced senescence (1)
- orofacial granulomatosis (1)
- outpatients (1)
- over-the-counter drugs (1)
- p53 (1)
- pan-RCC (1)
- panel sequencing (1)
- patient preferences (1)
- patient survival (1)
- pediatric (1)
- peginterferon bet-1a (1)
- pemphigoid (1)
- pemphigoid gestationis (1)
- perivascular epitheloid cell tumour (1)
- phakomatosis pigmentovascularis (1)
- phosphorylation (1)
- phthalazinone pyrazole (1)
- pityriasis rubra pilaris (1)
- plaque-type psoriasis (1)
- polymerase chain reaction (1)
- population pharmacokinetics (1)
- predictive marker (1)
- primary cutaneous follicular B-cell lymphoma (1)
- programmed cell death receptor-1 (1)
- programmed necrosis (1)
- protease inhibitors (1)
- protein kinase pathway (1)
- protein variant (1)
- pseudolymphoma (1)
- pustular exanthema (1)
- quinacrine (1)
- quinine (1)
- rare (1)
- re-induction (1)
- real-world data (1)
- regional recurrence (1)
- registry (1)
- regulatory T cell (1)
- reporter genes (1)
- resistance (1)
- response durability (1)
- responses (1)
- retinoblastoma protein (1)
- review (1)
- rhabdoid differentiation (1)
- rhabdoid melanoma (1)
- risk factor (1)
- satellitosis (1)
- secretion (1)
- senescence (1)
- severe acute respiratory syndrome coronavirus 2 (1)
- sex differences (1)
- shiitake dermatitis (1)
- shiitake mushrooms (1)
- shiitake-dermatite (1)
- signal inhibition (1)
- single nucleotide polymorphism (1)
- skin (1)
- skin cancer (1)
- skin carcinogenesis (1)
- skin neoplasms (1)
- skin reactions (1)
- skin squamous cell carcinoma (1)
- small interfering RNAs (1)
- smoking (1)
- somatic mutations (1)
- squamous cell (1)
- stress signaling (1)
- subtypes (1)
- suppression (1)
- suppressor cells (1)
- surgical and invasive medical procedures (1)
- survival (1)
- survivin (1)
- survivin T-cell reactivity (1)
- switching (1)
- systemic sclerosis (1)
- targeted sequencing (1)
- targeted therapy (1)
- tertiary lymphoid structures (1)
- toxic epidermal necrolysis (1)
- toxicity (1)
- trametinib (1)
- transcription factors (1)
- transcriptome (1)
- treatment options (1)
- triptan (1)
- tumor immunity (1)
- tumor microenvironment (1)
- tumor suppressor genes (1)
- tumor-draining lymph node (1)
- tumors (1)
- tumour immunology (1)
- tumourigenesis (1)
- typ XVII Collagen (1)
- type XVII collagen (1)
- utaneous adverse events (1)
- vascular endothelial growth (1)
- vasculitis (1)
- venereology (1)
- vesicles (1)
- vespula (1)
- viral carcinogenesis (1)
- virus (1)
- volumetric absorptive micro-sampling (VAMS) (1)
Institute
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (137) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 277775 (2)
Background
Correct recognition of risk factors enables individualized management and treatment of venom allergic patients.
Methods
Systematic research and review of current literature regarding the risk of (1) severe sting-induced anaphylaxis, (2) anaphylactic adverse event during venom immunotherapy (VIT), and (3) treatment failure.
Results and discussion
(1) Mastocytosis is the most important risk factor for severe sting-induced anaphylaxis. Hereditary α‑tryptasemia was recently identified as a genetic predictor of severe reactions. Older age is clearly associated with an increased risk; the respective impact of defined cardiovascular comorbidities has yet to be determined. Recent data do not support an aggravation of venom-induced anaphylaxis by intake of β‑blockers or angiotensin-converting enzyme (ACE) inhibitors. A higher risk in men can be attributed to more intensive exposure to stinging insects. (2) Anaphylactic side effects of VIT are most common during the buildup phase, particularly in the course of (ultra-)rush protocols involving a high number of injections and high cumulative daily doses. They are significantly more frequent during honeybee compared to Vespula VIT. Data supporting a negative effect of mastocytosis on the tolerability of VIT are scarce. Older age and cardiovascular medication are not associated with a higher incidence of VIT-induced anaphylaxis. (3) Relapsing anaphylactic reactions to both field and challenge stings are significantly more common during and after honeybee compared to Vespula VIT. Reports of severe field-sting reactions in mastocytosis patients suggest an increased risk of treatment failure which may be overcome by higher maintenance doses and longer duration of VIT.
Background and objectives
Bullous pemphigoid (BP) is associated with neuropsychiatric disorders. Other comorbid diseases are discussed controversially. We evaluated the prevalence of comorbidity in BP patients in a representative area of Germany.
Patients and methods
Medical files of all BP patients treated at the Department of Dermatology, University Hospital Würzburg, Germany, between June 2002 and May 2013 were retrospectively reviewed. Bullous pemphigoid was diagnosed based on established criteria. For each patient, two controls were individually matched. Records were evaluated for age, sex, laboratory values, concomitant medication and comorbidity. Conditional logistic regression, multivariable regression analysis and complex regression models were performed to compare results.
Results
300 BP patients were identified and compared to 583 controls. Bullous pemphigoid was associated with neuropsychiatric disorders as well as laboratory abnormalities including leukocytosis and eosinophilia. Importantly, a highly significant association of BP with anemia (OR 2.127; 95 % CI 1.532–2.953) and renal impairment (OR 2.218; 95 % CI 1.643–2.993) was identified. No association was found with malignancy and arterial hypertension.
Conclusions
Our data revealed an increased frequency of anemia and renal impairment in BP patients. In accordance with previous studies the strong association for neuropsychiatric disorders was confirmed (p < 0.0005).
The development of two conventional dendritic cells (DC) subsets (cDC1 and cDC2) and the plasmacytoid DC (pDC) in vivo and in cultures of bone marrow (BM) cells is mediated by the growth factor Flt3L. However, little is known about the factors that direct the development of the individual DC subsets. Here, we describe the selective in vitro generation of murine ESAM\(^{low}\) CD103\(^{-}\) XCR1\(^{-}\) CD172a\(^{+}\) CD11b\(^{+}\) cDC2 from BM by treatment with a combination of Flt3L, LIF, and IL‐10 (collectively named as FL10). FL10 promotes common dendritic cell progenitors (CDP) proliferation in the cultures, similar to Flt3L and CDP sorted and cultured in FL10 generate exclusively cDC2. These cDC2 express the transcription factors Irf4, Klf4, and Notch2, and their growth is reduced using BM from Irf4\(^{-/-}\) mice, but the expression of Batf3 and Tcf4 is low. Functionally they respond to TLR3, TLR4, and TLR9 signals by upregulation of the surface maturation markers MHC II, CD80, CD86, and CD40, while they poorly secrete proinflammatory cytokines. Peptide presentation to TCR transgenic OT‐II cells induced proliferation and IFN‐γ production that was similar to GM‐CSF‐generated BM‐DC and higher than Flt3L‐generated DC. Together, our data support that FL10 culture of BM cells selectively promotes CDP‐derived ESAM\(^{low}\) cDC2 (cDC2B) development and survival in vitro.
Forkhead box O (FoxO) transcription factors are conserved proteins involved in the regulation of life span and age-related diseases, such as diabetes and cancer. Stress stimuli or growth factor deprivation promotes nuclear localization and activation of FoxO proteins, which—depending on the cellular context—can lead to cell cycle arrest or apoptosis. In endothelial cells (ECs), they further regulate angiogenesis and may promote inflammation and vessel destabilization implicating a role of FoxOs in vascular diseases. In several cancers, FoxOs exert a tumor-suppressive function by regulating proliferation and survival. We and others have previously shown that FoxOs can regulate these processes via two different mechanisms: by direct binding to forkhead-responsive elements at the promoter of target genes or by a poorly understood alternative process that does not require direct DNA binding and regulates key targets in primary human ECs. Here, we performed an interaction study in ECs to identify new nuclear FoxO3 interaction partners that might contribute to FoxO-dependent gene regulation. Mass spectrometry analysis of FoxO3-interacting proteins revealed transformation/transcription domain–associated protein (TRRAP), a member of multiple histone acetyltransferase complexes, as a novel binding partner of FoxO family proteins. We demonstrate that TRRAP is required to support FoxO3 transactivation and FoxO3-dependent G1 arrest and apoptosis in ECs via transcriptional activation of the cyclin-dependent kinase inhibitor p27\(^{kip1}\) and the proapoptotic B-cell lymphoma 2 family member, BIM. Moreover, FoxO–TRRAP interaction could explain FoxO-induced alternative gene regulation via TRRAP-dependent recruitment to target promoters lacking forkhead-responsive element sequences.
Outcome of a de-labelling algorithm compared with results of penicillin (β-lactam) allergy testing
(2022)
Background
Penicillin allergy labels frequently impede guideline-directed treatment with a penicillin or other β-lactam antibiotics. Despite presumed allergy, targeted questioning may indicate a low probability of sensitization and permit reasonably safe administration of the antibiotic in question. In this study, we evaluated a standardized algorithm aiming to differentiate non-allergic patients from those with true allergic β-lactam hypersensitivity.
Methods
We retrospectively applied a de-labelling algorithm in 800 consecutive patients with suspected β-lactam hypersensitivity. All had undergone complete allergy work-up permitting to definitely exclude or diagnose β-lactam allergy between 2009 and 2019.
Results
In 595 (74.4%) out of 800 cases evaluated, β-lactam allergy could be excluded by negative challenge testing. IgE-mediated anaphylaxis was diagnosed in 70 (8.7%) patients, delayed-type hypersensitivity in 135 (16.9%). In 62 (88.6%) anaphylaxis cases, the algorithm correctly advised to use an alternative antibiotic. Accuracy was higher in patients with moderate to severe anaphylaxis (97.7%) compared to those with a history of mild reactions (73.1%). The algorithm correctly identified 122 (90.4%) patients with proven delayed-type hypersensitivity. It permitted de-labelling in 330 (55.5%) out of 595 patients with diagnostic exclusion of penicillin hypersensitivity, but failed to identify the remaining 265 (44.5%) as low-risk cases.
Conclusions
The algorithm detected 89.8% of cases with penicillin (β-lactam) allergy, sensitivity was optimal for moderate to severe anaphylaxis. Study data justify the implementation of a standardized de-labelling algorithm under close supervision in order to permit guideline-directed treatment and reduce the use of broad-spectrum antibiotics as part of an antibiotic stewardship program.
Background
Epithelioid haemangioma (EH) arising from the skin is a benign vascular tumour with marked inflammatory cell infiltration, which exhibits a high tendency to persist and frequently recurs after resection. So far, the underlying pathogenesis is largely elusive.
Objectives
To identify genetic alterations by next-generation sequencing and/or droplet digital polymerase chain reaction (ddPCR) in cutaneous EH.
Methods
DNA and RNA from an EH lesion of an index patient were subjected to whole-genome and RNA sequencing. Multiplex PCR-based panel sequencing of genomic DNA isolated from archival formalin-fixed paraffin-embedded tissue of 18 patients with cutaneous EH was performed. ddPCR was used to confirm mutations.
Results
We identified somatic mutations in genes of the mitogen-activated protein kinase (MAPK) pathway (MAP2K1 and KRAS) in cutaneous EH biopsies. By ddPCR we could confirm the recurrent presence of activating, low-frequency mutations affecting MAP2K1. In total, nine out of 18 patients analysed showed activating MAPK pathway mutations, which were mutually exclusive. Comparative analysis of tissue areas enriched for lymphatic infiltrate or aberrant endothelial cells, respectively, revealed an association of these mutations with the presence of endothelial cells.
Conclusions
Taken together, our data suggest that EH shows somatic mutations in genes of the MAPK pathway which might contribute to the formation of this benign tumour.
Antibody–drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Such drugs consist in a monoclonal antibody linked to a cytotoxic agent, allowing a specific cytotoxicity to tumor cells. In recent years, tremendous progress has been observed in therapeutic approaches for advanced skin cancer patients. In this regard, targeted therapies (e.g., kinase inhibitors) or immune checkpoint-blocking antibodies outperformed conventional chemotherapy, with proven benefit to survival. Nevertheless, primary and acquired resistances as well as adverse events remain limitations of these therapies. Therefore, ADCs appear as an emerging therapeutic option in oncodermatology. After providing an overview of ADC design and development, the goal of this article is to review the potential ADC indications in the field of oncodermatology.
Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 patients with metastatic UM treated with ICB were included from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of ICB re-induction, two cohorts were compared: patients who received at least one ICB re-induction (cohort A, n = 52) versus those who received only one treatment line of ICB (cohort B, n = 125). In cohort A, a transient benefit of overall survival (OS) was observed at 6 and 12 months after the treatment start of ICB. There was no significant difference in OS between both groups (p = 0.1) with a median OS of 16.2 months (cohort A, 95% CI: 11.1–23.8) versus 9.4 months (cohort B, 95% CI: 6.1–14.9). Patients receiving re-induction of ICB (cohort A) had similar response rates compared to those receiving ICB once. Re-induction of ICB may yield a clinical benefit for a small subgroup of patients even after resistance or development of toxicities.
Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation. Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease with response rates to programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) inhibition of up to 62%. However, primary and secondary resistance to PD-1/PD-L1 inhibition remains a so far unsolved clinical challenge since effective and safe treatment options for these patients are lacking.Fourteen patients with advanced (non-resectable stage III or stage IV, Union international contre le cancer 2017) Merkel cell carcinoma with primary resistance to the PD-L1 inhibitor avelumab receiving subsequent therapy (second or later line) with ipilimumab plus nivolumab (IPI/NIVO) were identified in the prospective multicenter skin cancer registry ADOREG. Five of these 14 patients were reported previously and were included in this analysis with additional follow-up. Overall response rate, progression-free survival (PFS), overall survival (OS) and adverse events were analyzed.All 14 patients received avelumab as first-line treatment. Thereof, 12 patients had shown primary resistance with progressive disease in the first tumor assessment, while two patients had initially experienced a short-lived stabilization (stable disease). Six patients had at least one systemic treatment in between avelumab and IPI/NIVO. In total, 7 patients responded to IPI/NIVO (overall response rate 50%), and response was ongoing in 4 responders at last follow-up. After a median follow-up of 18.85 months, median PFS was 5.07 months (95% CI 2.43—not available (NA)), and median OS was not reached. PFS rates at 12 months and 24 months were 42.9% and 26.8 %, respectively. The OS rate at 36 months was 64.3%. Only 3 (21%) patients did not receive all 4 cycles of IPI/NIVO due to immune-related adverse events.In this multicenter evaluation, we observed high response rates, a durable benefit and promising OS rates after treatment with later-line combined IPI/NIVO. In conclusion, our patient cohort supports our prior findings with an encouraging activity of second-line or later-line IPI/NIVO in patients with anti-PD-L1-refractory Merkel cell carcinoma.